TRT optimization claims on TikTok: what the studies actually say

What did @alex.optimize actually say?

The creator ran through four main downsides of testosterone replacement therapy: suppression of the HPT axis (which he called the HPT-A axis), estrogenic side effects like water retention and gynecomastia, acceleration of male pattern baldness in genetically predisposed men, and elevated hemoglobin and hematocrit that can thicken blood. He also mentioned HCG and gonadorelin as tools to preserve testicular function and fertility, and aromatase inhibitors as a countermeasure for estrogen-related issues. To his credit, he framed the whole thing as a reason to work with a physician rather than ordering drugs from unregulated sources.

He closed with a pitch for Gravity Wellness, a telehealth clinic he appears affiliated with, offering blood work review and individualized protocols across all 50 states.

Does the science back this up?

Mostly, yes, with a few places where the framing gets sloppy or incomplete. The core biology here is well-established.

HPT axis suppression is not a risk, it is a near-certain outcome of exogenous testosterone use. The hypothalamic-pituitary-gonadal axis responds to circulating androgens via negative feedback, and exogenous testosterone reliably suppresses LH and FSH, which drives testicular atrophy and spermatogenesis decline. This is documented thoroughly in the literature, including Coviello et al. (2004, Journal of Clinical Endocrinology and Metabolism), who showed dose-dependent suppression of gonadotropins with testosterone administration.

On estrogen: testosterone aromatizes to estradiol, and elevated estradiol can contribute to gynecomastia and water retention in some men. However, the blanket co-prescribing of aromatase inhibitors is more common in commercial telehealth than it is in academic endocrinology guidelines. The Endocrine Society's 2018 clinical practice guidelines do not recommend routine AI use and warn that over-suppression of estradiol carries its own risks.

Erythrocytosis (elevated hemoglobin and hematocrit) is a real and well-documented adverse effect. The AUA and Endocrine Society both flag hematocrit above 54% as a threshold requiring dose reduction or phlebotomy. The cardiovascular risk from TRT-related erythrocytosis is an active area of research, and the claim that it is "never been an issue if you're on the proper dose" is an overstatement.

What did they get wrong (or right)?

A few things stand out as either meaningfully wrong or worth flagging.

First, he called it the "HPT-A axis." The standard term is the HPG axis, hypothalamic-pituitary-gonadal. The "A" likely refers to the adrenal component, but this is not standard nomenclature and could confuse viewers trying to do their own research.

Second, his framing that erythrocytosis "is never been an issue if you're on the proper dose" undersells a legitimate clinical concern. Erythrocytosis is one of the most common adverse effects of TRT, occurring in roughly 18-25% of patients in some estimates (Bachman et al., 2010, Journal of Clinical Endocrinology and Metabolism). Dose matters, but individual variability is significant.

Third, he used the word "antibiotics" when he clearly meant "anabolics" or supraphysiological doses. This is almost certainly a verbal slip, but in a 110,000-view video on a medical topic, it is worth noting.

On the positive side, his point about DHT-driven hair loss being genetically contingent is accurate. Testosterone converts to dihydrotestosterone via 5-alpha reductase, and androgenic alopecia requires both androgen sensitivity and genetic predisposition. He is correct that TRT does not cause hair loss in men without that underlying susceptibility.

What should you actually know?

If you are considering TRT, the side effect profile here is real and the general framework is sound, but a few things deserve more nuance than a short-form video can give.

• HPG suppression is essentially universal with exogenous testosterone. HCG can preserve testicular volume and some spermatogenesis, but it does not fully replicate normal gonadotropin function. Gonadorelin is used in some protocols but evidence on its effectiveness at preserving fertility compared to HCG is still limited.
• Aromatase inhibitors are not benign add-ons. Low estradiol in men is associated with reduced bone density, mood changes, and metabolic issues. Routine AI co-prescribing without monitoring estradiol levels is not guideline-supported.
• Hemoglobin and hematocrit should be monitored on a schedule, not assumed to be fine because the dose seems reasonable. The American Urological Association recommends checking hematocrit before starting TRT, then at 3-6 months, then annually.
• The cardiovascular safety of TRT at the population level is an evolving question. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found TRT was non-inferior to placebo for major adverse cardiovascular events in middle-aged men with hypogonadism and high cardiovascular risk, which is meaningful reassurance, though not a blanket safety guarantee.

Bottom line

This video is a reasonable lay overview of TRT side effects, not a dangerous one. The creator gets the big categories right and appropriately emphasizes physician oversight. The errors are mostly in precision and framing, not in the core claims. But "never been an issue on the proper dose" is the kind of confident minimization that can leave patients underprepared for real monitoring requirements.